Frontiers in Pharmacology
Cure8 research brief
Why This Matters
The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed prior biologics.
Who Should Pay Attention
Clinicians treating moderate‑to‑severe ulcerative colitis, researchers studying comparative effectiveness of advanced therapies, and patients (especially those with prior biologic exposure) considering advanced treatment options.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study pooled 32 randomized trials and used Bayesian network meta-analysis with a bivariate clustered ranking to visualize efficacy versus tolerability. For induction, upadacitinib, ustekinumab, and risankizumab were placed in the most favorable quadrant (high efficacy and tolerability).
For maintenance, upadacitinib 30 mg ranked highest for efficacy, while IL‑23 antagonists (guselkumab, mirikizumab) and lower‑dose upadacitinib showed favorable efficacy‑tolerability profiles.
The authors specifically note that in patients previously exposed to biologics, upadacitinib showed the highest relative efficacy and that guselkumab appears a promising biologic alternative based on current trial estimates.
Keep In Mind
Results are based on a network meta‑analysis of RCTs up to Nov 2025 and should be interpreted as comparative estimates that depend on included trial designs and populations. This classification is based on the article abstract provided.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Pharmacology
PublisherFrontiers Media SA
AuthorsXinyuan Zhang, Hao Qian, Lijuan Yang +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...